Matthew T. Wiley
CIK: 0001759703
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 25, 2026DFTX
Definium Therapeutics, Inc.
Sale(S)Direct3.1K shares at avg. $36.57$113K - Sep 14, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct125K shares- - Aug 12, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct62.5K shares- - Jun 25, 2026DFTX
Definium Therapeutics, Inc.
Sale(S)Direct2.9K shares at avg. $45.03$129K - Jun 22, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct62.5K shares- - Feb 3, 2026DFTX
Definium Therapeutics, Inc.
Award(A)Direct115K shares- - Mar 17, 2025MNMD
Mind Medicine (MindMed) Inc.
Award(A)DirectStock Option (Right to Buy)
350K shares- - Oct 3, 2024BTAI
BioXcel Therapeutics, Inc.
Sale(S)Direct6.3K shares at avg. $0.55$3K - Sep 17, 2024BTAI
BioXcel Therapeutics, Inc.
Award(A)Direct21.3K shares- - Sep 16, 2024BTAI
BioXcel Therapeutics, Inc.
Sale(S)Direct215 shares at avg. $0.69$148.522 - Sep 15, 2024BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct750 shares- - Jul 22, 2024BTAI
BioXcel Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
1.9K shares- - Jun 15, 2024BTAI
BioXcel Therapeutics, Inc.
Exercise(M)DirectRestricted Stock Units
750 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 25, 2026 |  DFTX Definium Therapeutics, Inc. | Sale(S) | 3,097 | $36.57 | $113,257 | Direct |
| Sep 14, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 125,000 | - | $0 | Direct |
| Aug 12, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 62,500 | - | $0 | Direct |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Sale(S) | 2,867 | $45.03 | $129,101 | Direct |
| Jun 22, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 62,500 | - | $0 | Direct |
| Feb 3, 2026 | DFTX Definium Therapeutics, Inc. | Award(A) | 115,000 | - | $0 | Direct |
| Mar 17, 2025 |  MNMD Mind Medicine (MindMed) Inc. | Award(A) Stock Option (Right to Buy) | 350,000 | - | - | Direct |
| Oct 3, 2024 |  BTAI BioXcel Therapeutics, Inc. | Sale(S) | 6,272 | $0.55 | $3,450 | Direct |
| Sep 17, 2024 | BTAI BioXcel Therapeutics, Inc. | Award(A) | 21,250 | - | $0 | Direct |
| Sep 16, 2024 | BTAI BioXcel Therapeutics, Inc. | Sale(S) | 215 | $0.69 | $149 | Direct |
| Sep 15, 2024 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 750 | - | $0 | Direct |
| Jul 22, 2024 | BTAI BioXcel Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 1,875 | - | - | Direct |
| Jun 15, 2024 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) Restricted Stock Units | 750 | - | - | Direct |
1-13 of 13 transactions
About Wiley Matthew T.
Wiley Matthew T. (SEC CIK 0001759703) files insider reports with the SEC as Chief Commercial Officer of Definium Therapeutics, Inc. (DFTX) and Chief Commercial Officer of BioXcel Therapeutics, Inc. (BTAI).
Signal8 holds 12 ownership filings by Wiley Matthew T. (1 Form 3, 11 Form 4), filed between Sep 17, 2024 and Sep 29, 2026. Those filings report 13 transactions, from Jun 15, 2024 to Sep 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Wiley Matthew T.'s filings is in NEW YORK, NY.
Recent filings by Wiley Matthew T.
- Sep 25, 2026: Open-market sale of DFTX shares (Form 4, code S).
- Sep 14, 2026: Grant or award of DFTX shares (Form 4, code A).
- Aug 12, 2026: Grant or award of DFTX shares (Form 4, code A).
- Jun 25, 2026: Open-market sale of DFTX shares (Form 4, code S).
- Jun 22, 2026: Grant or award of DFTX shares (Form 4, code A).
Other insiders filing for Definium Therapeutics, Inc. (DFTX)
- Karlin Daniel, Chief Medical Officer
- Barrow Robert, Chief Executive Officer
- Sullivan Mark, Chief Legal Officer
- Roberts Brandi, Chief Financial Officer
- Vallone Carol A, Director
- Krebs Andreas, Director